Quality Level
assay
≥95% (Gadolinium, elemental analysis)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
-10 to -25°C
General description
Gadobutrol is a highly water-soluble, macrocyclic, and electrically neutral gadolinium-based contrast agent (GBCA) used in contrast-enhanced MRI. Its active component is a non-ionic, paramagnetic complex of gadolinium (Gd3+) chelated with butrol, forming the distinct gadobutrol structure. Gadobutrol exhibits the greatest shortening of proton T1 relaxation times amongst all macrocyclic GBCAs, a key determinant of signal and contrast enhancement in MRI.
Application
Gadobutrol may be used to enhance diagnostic contrast in magnetic resonance imaging (MRI) of pathological lesions in the liver, central nervous system (CNS), kidney, and brain.
Biochem/physiol Actions
Water-soluble macrocyclic gadolinium-based MRI contrast agent excreted renally, enhances CNS pathology detection by improving blood-brain barrier visualization.
Upon intravenous administration, it enhances MRI sensitivity for detecting CNS pathologies associated with blood-brain barrier defects, areas of altered perfusion, or expanded extracellular space. This agent is particularly effective in visualizing tumors, inflammatory processes, and demyelinating diseases of the CNS. Gadobutrol is eliminated unchanged via the kidneys, with negligible extra-renal excretion.
Upon intravenous administration, it enhances MRI sensitivity for detecting CNS pathologies associated with blood-brain barrier defects, areas of altered perfusion, or expanded extracellular space. This agent is particularly effective in visualizing tumors, inflammatory processes, and demyelinating diseases of the CNS. Gadobutrol is eliminated unchanged via the kidneys, with negligible extra-renal excretion.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Laurie A Loevner et al.
Investigative radiology, 58(5), 307-313 (2023-02-03)
Developing new high relaxivity gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) allowing dose reduction while maintaining similar diagnostic efficacy is needed, especially in the context of gadolinium retention in tissues. This study aimed to demonstrate that contrast-enhanced MRI
Lesley J Scott
Clinical drug investigation, 38(8), 773-784 (2018-07-15)
Intravenous gadobutrol [Gadovist™ (EU); Gadavist® (USA)] is a second-generation, extracellular non-ionic macrocyclic gadolinium-based contrast agent (GBCA) that is approved for use in paediatric (including term neonates) and adult patients undergoing diagnostic contrast-enhanced (CE) MRI for visualization of pathological lesions in
Batuhan Bilgin et al.
Magnetic resonance imaging, 111, 67-73 (2024-04-12)
In the diagnosis of migraine, which is a neurovascular disease, gadolinium-based contrast agents (GBCAs) are used to rule out more serious conditions. On the other hand, it remains unclear as a scientific gap whether GBCAs may trigger migraine-related pain. The
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持